Events during the quarter
No material updates were provided in the report. The most relevant event during the quarter was the announcement of the outcome of the first preclinical study with NEX-22, where the results showed a controlled release of liraglutide, with plasma exposure over 28 days vs. ~2 days for liraglutide without the PharmaShell coating. Nanexa mentioned that the results will be confirmed with other preclinical studies while the optimisation of the formulation for a Ph 1 study is done in parallel. The NEX-20 study is proceeding according to plan, with estimated study completion before the end of June. No news on the NEX-18 programme were provided.
Aktuellt
SENASTE
